Asymmetrex Receives $0.42 Million Award from the NIH-National Heart, Lung, and Blood Institute to Develop the AlphaSTEM Test™ for Stem Cell Therapies and Drug Evaluations
On September 19, 2020, stem cell biotechnology company Asymmetrex was awarded a research and development grant from the NIH-NHLBI. The $0.42 million grant was awarded to support the company’s technical development and commercialization of its first-in-kind technology for specific and accurate counting of therapeutic tissue stem cells. On the heals of Asymmetrex’s recently published peer-reviewed report describing its development
Asymmetrex Reports the First Quantitation of “True” Tissue Stem Cells In Stem Cell History
In a recent report published in the journal OBM Transplantation, stem cell biotechnology company Asymmetrex reported the first counts of therapeutic “true” tissue stem cells in the history of stem cell science and medicine. This crucial research and clinical data, long-needed for accelerating the development of new and better stem cell medicines, is now readily
New Report Begins a New Era of Stem Cell Science and Medicine: Stem Cell Biotechnology Company Asymmetrex Tells How It Counts Therapeutic Tissue Stem Cells
In an August 28 special issue of the peer-reviewed online journal OBM Transplantation, stem cell biotechnology company Asymmetrex has now published a report describing how its technology for determining the specific dosage of therapeutic tissue stem cells works. The new technology is poised to revolutionize stem cell science and stem cell medicine by giving the
Asymmetrex’s Plan for Free Stem Cell Counting Is The Feature Story by Superb Crew News
This week, Massachusetts stem cell biotechnology company Asymmetrex was the feature news story by online business and technology news platform Superb Crew. The attraction for the choice of Asymmetrex is the company’s recent announcement of its plan to begin offering free tissue stem cell counting to the stem cell research, stem cell medicine, and pharmaceutical
Asymmetrex Announces Plans to Provide Free Tissue Stem Cell Counting
Today, June 16, Massachusetts stem cell biotechnology company Asymmetrex announces that it will begin offering free tissue stem cell counting on its company website. Scheduled for opening July 5, Independence Day weekend in the U.S., the company’s counting site will give academic scientists, stem cell medicine physicians, tissue stem cell suppliers, and drug companies a
Asymmetrex Director Sherley Addresses the Clinical Trial Supply Industry About the Benefits of Stem Cell Counting
May 12, 2020 In Arena International’s Clinical Trial Supply 2020 Virtual Experience online conference, Asymmetrex Director James Sherley discussed unique challenges in the supply chain of therapies for stem cell transplantation medicine, gene therapy, and gene-editing therapy that can be readily addressed by greater use of tissue stem cell counting technologies like those developed
medRxiv Publishes Asymmetrex Director’s Analysis of a Misread on COVID-19 Spread
Based on interrogation of public coronavirus data, Asymmetrex Director Sherley reports suspicion of a misread on COVID-19 spread In a preprint posted on medRxiv, Asymmetrex Director James Sherley reports the discovery of surprising relationships between how many positive coronavirus tests are found and how many tests were given. Everyone recognizes that if no tests were
SuperbCrew Interviews Asymmetrex CEO James L. Sherley
SuperbCrew, a business news website dedicated to covering innovative companies in the tech and business fields, recently interviewed Asymmetrex CEO James L. Sherley. Dr. Sherley discusses Asymmetrex’s background, his personal background, and the newly developed algorithms for rapid low cost counting of therapeutic tissue stem cells. “Together AlphaSTAR and Asymmetrex solve the 6 decades unsolved